Evobrutinib is the First and Only BTK Inhibitor to Demonstrate Reduction of a Key Biomarker of Neuronal Damage and Inflammation in Patients with MS
Go back to Evobrutinib is the First and Only BTK Inhibitor to Demonstrate Reduction of a Key Biomarker of Neuronal Damage and Inflammation in Patients with MS| (AMEX: MKKGY) | Delayed: 32.10 -0.34 (1.05%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $32.44 | 52 Week High | $ | |||
| Open | $32.03 | 52 Week Low | $ | |||
| Day High | $32.18 | P/E | N/A | |||
| Day Low | $31.77 | EPS | $ | |||
| Volume | 20,886 | |||||
| Merck & Co. (NYSE: MRK) | Delayed: 130.06 +3.06 (2.41%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $127.00 | 52 Week High | $65.46 | |||
| Open | $129.69 | 52 Week Low | $47.97 | |||
| Day High | $132.80 | P/E | 88.48 | |||
| Day Low | $128.76 | EPS | $1.47 | |||
| Volume | 6,167,613 | |||||
